Both remove amyloid from the brain and modestly slow early Alzheimer’s. They differ in how they are given, how long treatment lasts, the risk of brain swelling, and cost — differences that matter when choosing.
The drugmaker is buying a stake in the developer of the bispecific antibody that beat Keytruda in a lung cancer trial, and will test it alongside its antibody-drug conjugates in gastrointestinal cancers.
TrumpRx.gov lists discounted cash prices for brand-name drugs, including GLP-1s such as Zepbound, Wegovy and Ozempic. Here is how it works, what the prices are, and when it is — and isn’t — the cheapest option.
Children with idiopathic nephrotic syndrome have relied on steroids since the 1950s. Roche’s obinutuzumab is now approved to keep frequently relapsing patients in remission — offering a way off repeated steroid courses.
Tavapadon targets a narrower set of dopamine receptors than older drugs, aiming to ease movement symptoms with fewer of the side effects that make dopamine agonists hard to tolerate.
Lilly’s triple-hormone drug produced some of the largest weight loss ever seen in obesity trials. It isn’t approved yet — and a fast-growing online market selling it as a “research peptide” carries real dangers.
A University of Florida study of health records found people with memory problems who took glucosamine were more likely to progress to dementia. It is an association, not proof — but mouse experiments point to a plausible mechanism.
CRISPR Therapeutics’ CTX310 switches off the ANGPTL3 gene in the liver. One-year follow-up in a small first-in-human trial shows LDL and triglycerides stayed down with no serious treatment-related side effects.
Efsitora alfa turns 365 basal insulin injections a year into 52. It is the second weekly insulin cleared in the US this year — and a sign that diabetes care is shifting toward fewer, longer-acting doses.
Two Mount Sinai studies show how APOE4 turns key blood-vessel support cells into scar-forming cells, and that blocking one signal restored vessels in aged mice. It is early science with a clear lead.
Both promise to spot signs of dozens of cancers from a single blood draw, and neither is FDA-approved yet. Here is how they differ on what they measure, how often they raise false alarms, what happens after a positive result, and cost.
Both are once-daily GLP-1 tablets for weight loss, and both start at $149 a month. But they are very different drugs — and the differences in how you take them, how much weight people lost, and what higher doses cost are worth knowing.